Adicet Bio, Inc.(ACET)

NASDAQ Global Market

Sector: Healthcare | Industry: Biotechnology

Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.

Latest News & Analysis

$Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Refractory SLE: Learn about this potential breakthrough therapy and its implications for patients with lupus.$

Feb 21, 2025

Adicet Bio's ADI-001 Receives FDA Fast Track for SLE: Market Impact

Adicet Bio (ACET) gains momentum with FDA Fast Track for ADI-001 in SLE, advancing its pipeline amid key milestones. A look at market impact and future prospects.